

TRANSGENOMIC INC  
Form 3  
November 05, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Richards Leon		(Month/Day/Year)	TRANSGENOMIC INC [TBIO]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		10/31/2014		
C/O TRANSGENOMIC, INC.,Â 12325 EMMET STREET			(Check all applicable)	
	(Street)		<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below)	(specify below)
			Chief Accounting Officer	
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person
OMAHA,Â NEÂ 68164				
(City)	(State)	(Zip)		

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

(Instr. 5)

Stock Option (Right to Buy)	Â (1)	01/01/2023	Common Stock	4,166	\$ 7.56	D	Â
Stock Option (Right to Buy)	Â (2)	05/03/2023	Common Stock	1,458	\$ 4.2	D	Â
Stock Option (Right to Buy)	Â (3)	02/18/2024	Common Stock	3,000	\$ 5.54	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Richards Leon C/O TRANSGENOMIC, INC. 12325 EMMET STREET OMAHA, NE 68164	Â	Â	Â Chief Accounting Officer	Â

## Signatures

/s/ Leon  
Richards

11/05/2014

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The option was granted on 1/1/2013 and is exercisable in three equal annual installments. The first installment became exercisable on (1) January 1, 2014, and the next two installments will become exercisable on the second and third anniversary of the date of grant, subject to the reporting person's continued employment with the issuer on each such date.

The option was granted on 5/3/2013 and is exercisable in three equal annual installments. The first installment became exercisable on (2) May 3, 2014, and the next two installments will become exercisable on the second and third anniversary of the date of grant, subject to the reporting person's continued employment with the issuer on each such date.

The option was granted on 2/18/2014 and is exercisable as it vests. The option vests over a three-year period in substantially equal (3) installments, with 1/3 of the shares subject to the option vesting on each of the first, second and third anniversary of the date of grant, subject to the reporting person's continued employment with the issuer on each such date.

Â

### Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.